



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ovd et al.

Serial No.

10/542,169

Filed:

July 13, 2005

For: OPHTHALMIC COMPOSITIONS FOR TREATING

OCULAR HYPERTENSION

Art Unit: 1626 TBD Examiner:

\*Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Supplemental

## INFORMATION DISCLOSURE STATEMENT **UNDER 37 CFR 1.97**

Sir:

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- 3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
- Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

**RELATED APPLICATION** 

**MERCK CASE** 

**FILING DATE** 

## INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

U. S. SERIAL NUMBER

If th	is is inconvenient, additional copies will be submitted upon request.						
(	6. In accordance with 37 C.F.R. 1.97, (check one)						
	the attached information is filed within three months of the filing date of the captioned case.						
	the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.						
	the attached information is filed before the mailing of a first Office action after the filing of a request for continued examination under §1.114.						
	the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action, Notice of Allowance, or an action that otherwise closes prosecution in the application. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).						
$\checkmark$	each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.						
	each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the information disclosure statement.						
	no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.						
	Respectfu <b>kt/</b> submitted						

By: Sylvia A. Ayler
Attorney For Applicant(s)

Reg. No. 36,436
MERCK & CO., INC.
Patent Dept., RY60-30
P.O. Box 2000
Rahway, N.J. 07065-0907
(732)594-4909

Date: February 20, 2007

Substitute for form 1449B/PTO				COMPLETE IF KNOWN			
INFORMATION DISCLOSURE				Application Number	10/542,169		
STATEMENT BY APPLICANT			DIICANT	Filing Date	July 13, 2005		
			PLICANI	First Named Inventor	Boyd et al.		
			,	Group Art Unit	1626 FEB 2 2 2007		
(use as many sheets as necessary)			ecessary)	Examiner Name	TBD E		
et	1	of	1	Attorney Docket Number	21242P		

NON PATENT LITERATURE DOCUMENTS								
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.						
		V. K. Boltze et al., Chemische Struktur und Antiphlogistische Wirkung in der Reihe der Substituierten Indol-3-Essigsauren", 1980, pp. 1314-1325, Vol. 30, Drug Research.						
		G. Linari et al., "Substituted Anilides of 1-(p-Chlorobenzoly)-5-Methoxy-2Mehtyl-Indole-3-Acetic", 1973, Vol 23, No. 1, Drug Research.						
		·						
	-							

Examiner Signature	Date Considered	

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.